ZL-1310

DRUG6 trials

Sponsors

Zai Lab (US) LLC, Zai Lab (Shanghai) Co., Ltd., Amgen, Boehringer Ingelheim

Conditions

Extrapulmonary Neuroendocrine Carcinoma of Large Cell HistologyExtrapulmonary Neuroendocrine Carcinoma of Small Cell HistologyLarge Cell Neuroendocrine Lung CarcinomaSCLCSmall Cell Lung CancerSmall Cell Lung Cancer (SCLC)Small-cell Lung CancerSolid Tumors

Phase 1

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

RecruitingNCT06179069

Zai Lab (Shanghai) Co., Ltd.SCLC

Start: 2024-01-23End: 2027-07-31Target: 339Updated: 2026-08-21

A Study of ZL-1310 in Participants With Selected Solid Tumors

RecruitingNCT06885281

Zai Lab (Shanghai) Co., Ltd.Solid Tumors

Start: 2025-05-12End: 2028-04-01Target: 166Updated: 2026-08-21

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

RecruitingNCT07531095

AmgenSmall Cell Lung Cancer

Start: 2026-04-21End: 2031-05-21Target: 160Updated: 2026-08-21

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

Not yet recruitingNCT07707895

Boehringer IngelheimExtrapulmonary Neuroendocrine Carcinoma of Large Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Large Cell Neuroendocrine Lung Carcinoma +1

Start: 2026-09-29End: 2030-04-26Target: 60Updated: 2026-09-02

Phase 3

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

RecruitingNCT07218146

Zai Lab (Shanghai) Co., Ltd.Small-cell Lung Cancer

Start: 2025-11-30End: 2028-11-30Target: 480Updated: 2026-09-14

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer

Not yet recruitingCTIS2025-522818-23-00

Zai Lab (US) LLCSmall Cell Lung Cancer (SCLC)

Target: 131Updated: 2026-06-10

Related Papers

A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).

Journal of Clinical Oncology2026-05-28

Abstract CT189: Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors

Cancer Research2026-04-17

Abstract CT193: Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial

Cancer Research2026-04-17

ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update.

Journal of Clinical Oncology2025-05-285 citations